August 29, 2017 / 12:45 PM / 3 months ago

BRIEF-Urogen Pharma receives FDA fast track designation for Mitogel

Aug 29 (Reuters) - Urogen Pharma Ltd

* Urogen Pharma receives FDA fast track designation for Mitogel for the treatment of upper tract urothelial carcinoma (UTUC)

* Mitogel currently being evaluated in ongoing pivotal phase 3 olympus clinical trial in patients with low-grade UTUC Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below